Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-021669
Filing Date
2025-08-13
Accepted
2025-08-13 16:55:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6316
  Complete submission text file 0001415889-25-021669.txt   8268
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Subject) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92777 | Film No.: 251212556
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 10 ORINDA VIEW ROAD ORINDA CA 94563
Business Address 10 ORINDA VIEW ROAD ORINDA CA 94563 (646) 600-6438
Transcend Partners Opportunity Fund I LLC (Filed by) CIK: 0001832019 (see all company filings)

EIN.: 000000000 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A